ACRS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ACRS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Aclaris Therapeutics has the Profitability Rank of 3. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1. Operating Margin %Aclaris Therapeutics's Operating Margin % for the quarter that ended in Mar. 2024 was -672.69%. As of today, Aclaris Therapeutics's Piotroski F-Score is 3.
For the Diagnostics & Research subindustry, Aclaris Therapeutics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Aclaris Therapeutics's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Aclaris Therapeutics's Profitability Rank falls into.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Aclaris Therapeutics has the Profitability Rank of 3. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Aclaris Therapeutics's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:
Operating Margin % | = | Operating Income (Q: Mar. 2024 ) | / | Revenue (Q: Mar. 2024 ) |
= | -16.131 | / | 2.398 | |
= | -672.69 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Warning Sign:
Piotroski F-Score of 3 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Aclaris Therapeutics has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
Good Sign:
Aclaris Therapeutics Inc operating margin is expanding. Margin expansion is usually a good sign.
4. Consistency of the profitability
5. Predictability Rank
Thank you for viewing the detailed overview of Aclaris Therapeutics's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Joseph Monahan | officer: Chief Scientific Officer | C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087 |
Kevin Balthaser | officer: Chief Financial Officer | C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087 |
James Loerop | officer: Chief Business Officer | C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087 |
Douglas J. Manion | officer: Pres and COO | C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087 |
Neal Walker | director, officer: President and CEO | 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803 |
Andrew N Schiff | director | PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022 |
Gail Cawkwell | officer: Chief Medical Officer | C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087 |
Frank Ruffo | officer: Chief Financial Officer | C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355 |
David N. Gordon | officer: Chief Medical Officer | C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355 |
Kamil Ali-jackson | officer: Chief Legal Officer | C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355 |
James B. Tananbaum | 10 percent owner | 3052 PACIFIC AVENUE, SAN FRANCISCO CA 94115 |
Foresite Capital Management Iii, Llc | 10 percent owner | 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939 |
Foresite Capital Fund Iii, L.p. | 10 percent owner | 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111 |
Foresite Capital Fund Iv, L.p. | 10 percent owner | 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111 |
Foresite Capital Management Iv, Llc | 10 percent owner | 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939 |
From GuruFocus
By sperokesalga sperokesalga • 03-27-2023
By Value_Insider Value_Insider • 11-22-2022
By Marketwired • 08-07-2023
By PurpleRose PurpleRose • 08-01-2022
By sperokesalga sperokesalga • 02-09-2023
By Stock market mentor Stock market mentor • 01-06-2023
By Marketwired • 10-03-2023
By GuruFocusNews GuruFocusNews • 07-01-2022
By sperokesalga sperokesalga • 06-02-2023
By sperokesalga sperokesalga • 05-08-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.